Jefferies analyst Maury Raycroft lowered the price target on Compass Therapeutics (NASDAQ: CMPX) to $7.00 (from $8.00) while maintaining a Buy rating.

The analyst comments "CMPX updated pivotal BTC ph.II/III data guidance to 1Q25 (vs YE24), which we think is incremental given that enrollment completion remains on-track for mid'24. Near-term catalyst CRC ph.II top-line data also remains on-track for mid'24. For pipeline programs, co is initiating a ph.II for '471 monotx in advanced melanoma and continues to dose '8371 in initial ph.I. PT to $7 ($8 prior) due to increased share count."